Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00121745
Recruitment Status : Terminated (poor enrollment)
First Posted : July 21, 2005
Last Update Posted : December 20, 2007
Information provided by:
Epeius Biotechnologies

Brief Summary:
This is a dose-seeking study that will test the safety of increasing doses of Rexin-G, given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy. Rexin-G is a tumor-targeted gene therapy vector that contains a "killer" gene that blocks the action of the human cyclin G1 gene. Cyclin G1 is a cell cycle control element that plays an important role in cancer growth. When injected into a vein, the Rexin-GTM vector seeks out and accumulates in cancerous tumors, therefore, increasing the concentration of the drug in the cancerous tumors and not in normal neighbouring organs.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Genetic: Rexin-G Dose 1 Genetic: Rexin-G Dose 2 Genetic: Rexin-G Dose 3 Genetic: Rexin-G Dose 4 Phase 1

Detailed Description:

Pancreatic cancer is the fourth leading cause of cancer death in the United States. Every year, about 30,000 new patients are diagnosed with pancreatic cancer, and most will die within the year. The few patients that live beyond one year are those who have operable tumors whose cancer has not spread beyond the pancreas. There is no effective treatment for pancreatic cancer that impacts survival beyond a few more months. Therefore, innovative treatments are urgently needed. A number of experimental therapies are currently under investigation, and gene therapy is a viable therapeutic option.

A gene called cyclin G1 has been shown to play a very important part in cancer growth. In animal experiments, when this cyclin G1 gene is blocked, the cancer cells grow much slower or even die. This study will test the drug, Rexin-G, which contains a gene that works by getting rid of the cyclin G1 gene. The new gene will get into the tumor cells using a "vehicle" to carry it into the cells. The "vehicle" that will be used is a virus that has been changed so that it is not likely to cause disease. This "vehicle" is called a vector. When injected into a vein, the Rexin-G vector is designed to seek out and accumulate in cancerous tumors, therefore, increasing the concentration of the drug in the area of the cancer and not in normal neighbouring organs. When the killer gene gets into the cancer cell, it becomes part of the cell's genes and tells the cancer cell to begin using the new gene instead of the cyclin G1 gene. It is hoped that the Rexin-G will arrest the growth of the cancer or eradicate the tumor.

The goals of the study are to determine how much Rexin-G can be given to a patient, to assess how long Rexin-G stays in the body when injected into a vein, and if the drug would cause antibodies to form, transfer the gene to normal tissues or pass on the gene to another person or the person's offspring. The final goal is to determine if the Rexin-G vector can shrink the tumor by comparing the size of the tumor nodules measured by CT scan or MRI before and after the Rexin-G treatment.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Evaluation of Safety of Intravenous Infusion of a Pathotropic Vector Bearing a Cytocidal Cyclin G1 Construct (Rexin-G) as Intervention for Locally Advanced and Metastatic Pancreatic Cancer Refractory to Standard Chemotherapy
Study Start Date : July 2005
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Genetic: Rexin-G Dose 1
Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
Experimental: 2 Genetic: Rexin-G Dose 2
Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
Experimental: 3 Genetic: Rexin-G Dose 3

Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose

III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml

Experimental: 4 Genetic: Rexin-G Dose 4

Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose

IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml

Primary Outcome Measures :
  1. To determine the dose limiting toxicity and maximum tolerated dose of Rexin-G administered as intravenous infusions; To evaluate pharmacokinetics of Rexin-G [ Time Frame: 22 months ]

Secondary Outcome Measures :
  1. To assess anti-tumor activity of intravenously administered Rexin-G and obtain preliminary data on biochemical markers of tumor response [ Time Frame: 22 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older.
  • Locally advanced or metastatic pancreatic cancer.
  • Histologic or cytologic confirmation at diagnosis or recurrence of pancreatic cancer
  • Measurable disease (RECIST) criteria. Tumor lesions that are situated in a previously irradiated area are not considered measurable, except if there is radiologically confirmed progression of disease within the radiation fields after radiation was completed.
  • Failed gemcitabine chemotherapy as indicated by disease progression ≤ 6 months from last gemcitabine treatment
  • Two or less than 2 chemotherapy regimens for recurrent/progressive disease.
  • Adequate hepatic function based on laboratory values obtained less than 7 days prior to registration:

    • Total bilirubin <2.0 mg/dL;
    • AST < 2 x ULN;
    • AST < 2 x ULN;
    • Hgb > 9.0 gm/dL;
    • PT < ULN;
    • PTT <ULN;
    • Albumin > 3.0 gm/dL;
    • Alkaline phosphatase < 3 x ULN;
    • Absolute granulocyte count > 1000/uL;
    • Platelet count > 100,000/uL;
    • Serum creatinine < 1.2 mg/dL for females; < 1.4 mg/dL for males.
  • ECOG performance status (PS) 0 or 1.
  • Ability to provide informed consent.
  • Life expectancy 12 weeks or greater.
  • Male participants should be willing to provide semen samples at required intervals. Inability of the patient to provide all semen samples does not make the patient ineligible. (EXCEPTION: If the patient has been vasectomized. To be noted in the study file).
  • Fertile patients agree to use barrier contraception (condoms plus spermicidal jelly) during the vector infusion period and for six weeks after infusion.
  • Accessibility of peripheral or central IV line which is adequate for infusions of investigational agent.

Exclusion Criteria:

  • Prior malignancy. (EXCEPTION: Patients who are disease free ≥ 5 years and/or patients with non-melanoma skin cancer, Stage I breast cancer, CIS of cervix)
  • Any of the following:

    • Pregnant women;
    • Nursing women;
    • Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], or abstinence, etc.). This study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown.
  • Patients who are HIV+, HBV+ or HCV+.
  • Clinically significant ascites causing symptoms or requiring therapeutic paracentesis.
  • Medical, psychiatric, or social conditions that would compromise successful adherence to this protocol.
  • Concomitant use of other chemotherapeutic, viral or immunotherapeutic agents is not allowed during the 6-week study period.
  • ≤ 4 weeks from radiation therapy of their pancreatic primary or ≤ 2 weeks from palliative radiation therapy to metastatic sites.
  • ≤ 4 weeks from prior chemotherapy.
  • History of congestive heart failure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00121745

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Epeius Biotechnologies
Principal Investigator: Evanthia Galanis, M.D. Mayo Clinic - Rochester, Minnesota

Responsible Party: Erlinda M. Gordon, M.D., Epeius Biotechnologies Corporation Identifier: NCT00121745     History of Changes
Other Study ID Numbers: MC044C
First Posted: July 21, 2005    Key Record Dates
Last Update Posted: December 20, 2007
Last Verified: December 2007

Keywords provided by Epeius Biotechnologies:
gene transfer
cell cycle control
cancer gene therapy
pathotropic targeting
tumor targeted retroviral vector

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases